Jul 14, 2026
If your brand is approaching its loss of exclusivity you maybe starting to think about the launch of generics. You’ll be concerned with how long you can maintain margin and retain he brand. Is it worth brand equalising, and if so for how long? In these...
Jun 30, 2026
The graph shows the average PI price for a group of respiratory products. Each of the branded products shown in the chart is heavily effected by parallel imports as they were the most commonly traded PI respiratory products in May 2026, and in the top 12 of all...
Mar 5, 2026
There has been a lot of discussion about Category H at recent events, online and on socials. Charles Joynson, WaveData MD, poses the question; ‘Will it cut another group of generics to the bone and seriously damage pharmacy and supplier profitability? Or will it...
Feb 16, 2026
We know that pharmacies buying generics are making a loss when they dispense. Previous analysis, available on the Wavedata.co.uk articles page, shows that over 1200 generic products each month are unprofitable. However, what about parallel imports, are they profitable...
Feb 13, 2026
Charles Joynson, WaveData MD, was delighted to join Jeremy Durrant, Director of Communications and External Engagement at Medicines UK, in the latest episode of their podcast Medicine Matters. It’s a lively discussion, looking at pricing trends over the last 12...
Sep 16, 2025
Leslie Galloway, EMIG Chairman, shared his analysis of VPAG. Here’s Charles’ key takeaways: · The NHS VPAG rebate is £1bn over 3 years and so is a fixed rebate with risk share. · Global Pharma CEOs have asked for lower rebates and a better deal, that...
